皮肌炎的发病率、患病率与死亡率:一项基于人群的队列研究
该研究基于美国Olmsted County 1995至2019年人群队列,采用EULAR/ACR标准确认皮肌炎病例,年龄性别调整后发病率为1.1/10万人年,患病率为13/10万;肌病型皮肌炎标准化死亡比显著升高(3.1),而临床无肌病性皮肌炎(CADM)未见死亡率升高。
要点
- 皮肌炎调整后发病率1.1/10万人年,患病率13/10万。
- 肌病型皮肌炎SMR为3.1(95%CI 1.1-6.8),CADM的SMR为1.1(95%CI 0.2-3.3)。
- ≥2个皮肌炎诊断代码的阳性预测值仅49%(40/82)。
核心结论
- 基于人群的皮肌炎发病率和患病率高于既往报道。
- 肌病型皮肌炎患者死亡率显著升高,而CADM患者死亡率未见显著升高。
研究设计与样本
- 基于人群的队列研究,纳入1995年1月1日至2019年12月31日Olmsted County的皮肌炎病例。
- 手动审查至少1个皮肌炎或多发性肌炎诊断代码的个体,依据EULAR/ACR标准、专科医生诊断和/或Bohan和Peter标准确认。
- 发病率和患病率按2000年美国非西班牙裔白人人口进行年龄和性别调整,患病率估计日期为2015年1月1日。
- 共确认40例皮肌炎,其中29例为1995至2019年新发病例;平均年龄57岁,26例(90%)为女性,12例(41%)为CADM;中位随访8.2年。
主要发现
- 总体调整后发病率为1.1/10万人年(95%CI 0.7-1.5),患病率为13/10万(95%CI 6-19)。
- 肌病型皮肌炎SMR为3.1(95%CI 1.1-6.8),CADM的SMR为1.1(95%CI 0.2-3.3)。
- ≥2个皮肌炎诊断代码的阳性预测值为40/82(49%)。
关键数值与推荐
- 采用EULAR/ACR标准、专科医生诊断和/或Bohan和Peter标准确认皮肌炎。
- 调整后发病率1.1/10万人年(95%CI 0.7-1.5),患病率13/10万(95%CI 6-19)。
- 肌病型皮肌炎SMR 3.1(95%CI 1.1-6.8),CADM SMR 1.1(95%CI 0.2-3.3)。
- ≥2个皮肌炎诊断代码的阳性预测值49%(40/82)。
临床怎么用
- 基于人群数据提示皮肌炎发病率与患病率高于既往报道,应关注肌病型皮肌炎患者死亡风险升高。
- CADM患者死亡率未见显著升高,但仍需长期随访。
- 仅凭诊断代码识别皮肌炎阳性预测值较低(49%),需结合病历审查确认。
局限性
- 研究基于单一县人群,样本量较小(29例新发病例)。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We aimed to determine the population-based incidence, prevalence, and mortality of dermatomyositis (DM) using European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) criteria. METHODS: This population-based cohort study included incident DM from January 1, 1995 to December 31, 2019. We manually reviewed all individuals with at least 1 code for DM or polymyositis to determine if they met EULAR/ACR criteria, subspecialty physician diagnosis, and/or Bohan and Peter criteria. We age- and sex-adjusted incidence and prevalence estimates to the US non-Hispanic White year 2000 population and estimated prevalence on January 1, 2015. Standardized mortality ratios (SMRs) with 95% confidence intervals (95% CIs) compared observed to expected mortality adjusting for age, sex, and year. RESULTS: We identified 40 cases of verified DM, with 29 cases incident in Olmsted County from 1995 to 2019. The mean age was 57 years, 26 (90%) were female, and 12 (41%) had clinically amyopathic DM (CADM). The median follow-up time was 8.2 years. The overall adjusted incidence of DM was 1.1 (95% CI 0.7-1.5) per 100,000 person-years, and prevalence was 13 (95% CI 6-19) per 100,000. The SMR was significantly elevated among the myopathic DM cases (3.1 [95% CI 1.1-6.8]) but not CADM cases (1.1 [95% CI 0.2-3.3]). The positive predictive value of ≥2 DM codes was only 40 of 82 (49%). CONCLUSION: This population-based study found that DM incidence and prevalence were higher than previously reported. Mortality was significantly elevated for myopathic DM but not for CADM.
引用
- Kronzer VL, Kimbrough BA, Crowson CS, et al. Incidence, Prevalence, and Mortality of Dermatomyositis: A Population-Based Cohort Study. Arthritis Care Res (Hoboken). 2022. PMID: 34549549. doi:10.1002/acr.24786
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。